Enfortumab vedotin
- Generic Name
- Enfortumab vedotin
- Brand Names
- Padcev
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1346452-25-2
- Unique Ingredient Identifier
- DLE8519RWM
- Background
Enfortumab vedotin is an antibody-drug conjugate used in the treatment of patients with advanced, treatment-resistant urothelial cancers. It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting chemotherapeutic agent, monomethyl auristatin E (MMAE), joined by a protease-cleavable link. It is similar to bren...
- Indication
Enfortumab vedotin is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor, and platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced, or metastatic setting. Enfortumab vedoti...
- Associated Conditions
- Locally Advanced Urothelial Cancer, Locally Advanced or Metastatic Urothelial Carcinoma (UC), Metastatic Urothelial Cancer
- Associated Therapies
- -
Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC
- Conditions
- Interventions
- First Posted Date
- 2024-08-14
- Last Posted Date
- 2024-12-12
- Target Recruit Count
- 40
- Registration Number
- NCT06553885
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2024-07-10
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Vasgene Therapeutics, Inc
- Target Recruit Count
- 700
- Registration Number
- NCT06493552
Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE)
- Conditions
- Interventions
- First Posted Date
- 2024-05-30
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 41
- Registration Number
- NCT06434350
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Enfortumab Vedotin and Stereotactic Radiation for Localized, Cisplatin Ineligible Muscle Invasive Bladder Cancer
- First Posted Date
- 2024-05-01
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 19
- Registration Number
- NCT06394570
- Locations
- 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States
Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Cisplatin-eligible Upper Tract Urothelial Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-04-10
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 32
- Registration Number
- NCT06356155
- Locations
- 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Enfortumab Vedotin for the Treatment of Patients with Metastatic or Unresectable Squamous Cell Carcinoma of the Penis
- First Posted Date
- 2023-10-27
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 28
- Registration Number
- NCT06104618
- Locations
- 🇺🇸
Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
🇺🇸Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸Mayo Clinic in Rochester, Rochester, Minnesota, United States
Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)
- Conditions
- Interventions
- First Posted Date
- 2023-09-18
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 68
- Registration Number
- NCT06041503
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection
- First Posted Date
- 2023-08-25
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Astellas Pharma Korea, Inc.
- Target Recruit Count
- 235
- Registration Number
- NCT06011954
- Locations
- 🇰🇷
Site KR82001, Goyang-si, Gyeonggi-do, Korea, Republic of
🇰🇷Site KR82012, Suwon-si, Gyeonggi-do, Korea, Republic of
🇰🇷Site KR82008, Suwon-si, Gyeonggi-do, Korea, Republic of
Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-06-28
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 70
- Registration Number
- NCT05923190
- Locations
- 🇺🇸
Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania, United States
Enfortumab Vedotin in Previously Treated Locally Advanced or Metastatic Pancreatic Cancer (EPIC)
- Conditions
- Interventions
- First Posted Date
- 2023-06-23
- Last Posted Date
- 2023-07-05
- Lead Sponsor
- University of Kansas Medical Center
- Target Recruit Count
- 28
- Registration Number
- NCT05915351
- Locations
- 🇺🇸
University of Kansas Cancer Center, Kansas City, Kansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.